A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients.
antibody mediated rejection
kidney transplantation
plasmapheresis
rejection
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
30
09
2022
received:
13
08
2022
accepted:
03
10
2022
medline:
28
4
2023
pubmed:
7
10
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.
Identifiants
pubmed: 36201223
doi: 10.1111/1744-9987.13937
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
428-434Informations de copyright
© 2022 International Society for Apheresis and Japanese Society for Apheresis.
Références
Axelrod DA, Schnitzler MA, Xiao H, Irish W, Tuttle-Newhall E, Chang SH, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018;18(5):1168-76.
Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. OPTN/SRTR 2019 Annual Data Report: kidney. Am J Transplant. 2021;21(Suppl 2):21-137.
Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant. 2007;7(1):117-21.
Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2018;29(2):591-605.
Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016;100(2):391-9.
Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70(6):887-95.
Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66(11):1460-4.
Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033-41.
Böhmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol. 2001;12(11):2482-9.
Pretagostini R, Berloco P, Poli L, et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J. 1996;42(5):M645-8.
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-83.
Caliskan Y, Karahan G, Akgul SU, Mirioglu S, Ozluk Y, Yazici H, et al. LIMS1 risk genotype and T-cell mediated rejection in kidney transplant recipients. Nephrol Dial Transplant. 2021;36:2120-9.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org/ (2013). Accessed 25 Jul 2020.
Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation. 2020;104(5):911-22.
Redfield RR, Ellis TM, Zhong W, Scalea JR, Zens TJ, Mandelbrot D, et al. Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol. 2016;77(4):346-52.
Rafiq MA, de Boccardo G, Schröppel B, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant. 2009;23(6):951-7.
Tan M, Hudson F, Brewin G, Holdsworth R, Cohney S. Longer term outcomes following antibody mediated rejection (AbMR) in renal transplant recipients [abstract]. Immunol Cell Biol. 2009;87(6):A1-A28.
Lefaucheur C, Loupy A, Vernerey D, Duong-van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013;381(9863):313-9.
Crew R, Patel S, Morris H, Chiles M, Ratner L. Long term outcomes following antibody mediated rejection (AMR) in renal transplant recipients [abstract]. Am J Transplant. 2016;16(suppl 3):708-9.
Perrottet N, Golshayan D, Rotman S, Moll S, Hopfer H, Catana E, et al. Acute antibody-mediated rejection and its treatment in kidney transplantation: Report from a National Cohort Study [abstract]. Transplantation. 2018;102:S93.
Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. Transplantation. 2019;103(11):2397-404.
Jain D, Rajab A, Young JS, Yin D, Nadasdy T, Chong AS, et al. Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020;20(10):2675-85.
Ionescu L, Urschel S. Memory B cells and long-lived plasma cells. Transplantation. 2019;103(5):890-8.
Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome. Ther Apher. 2002;6(2):163-6.
Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. Transplant Rev (Orlando). 2017;31(2):87-95.
Chung BH, Kim Y, Jeong HS, Hong YA, Choi BS, Park CW, et al. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. Transpl Immunol. 2014;31(3):140-4.
Bachelet T, Nodimar C, Taupin JL, Lepreux S, Moreau K, Morel D, et al. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. Clin Transplant. 2015;29(5):439-46.